{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=5&state=Texas", "query": { "state": "Texas", "city": "Houston", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 22473, "total_pages": 2248, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=6&state=Texas&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=4&state=Texas&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T01:42:30.964Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002063", "title": "Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-11-01T01:42:30.964Z", "location_count": 8, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002063" }, { "nct_id": "NCT01857193", "title": "Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "ribociclib (LEE011)", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Everolimus (RAD001)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 132, "start_date": "2013-09-06", "completion_date": "2020-04-16", "has_results": false, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-11-01T01:42:30.964Z", "location_count": 8, "location_summary": "Fayetteville, Arkansas • Miami, Florida • Boston, Massachusetts + 5 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01857193" }, { "nct_id": "NCT04663321", "title": "Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Treatment Resistant Depression" ], "interventions": [ { "name": "MK-1942", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 99, "start_date": "2021-05-20", "completion_date": "2023-09-08", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-11-01T01:42:30.964Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Colton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04663321" }, { "nct_id": "NCT01813214", "title": "The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2013-03", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-11-01T01:42:30.964Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Houston, Texas + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01813214" }, { "nct_id": "NCT03491904", "title": "To Assess the Patients' Ability to Self-Administer Fasinumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Osteoarthritis, Knee", "Osteoarthritis, Hip" ], "interventions": [ { "name": "Fasinumab AI", "type": "DRUG" }, { "name": "Fasinumab PFS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2019-01-23", "completion_date": "2020-12-15", "has_results": false, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-11-01T01:42:30.964Z", "location_count": 23, "location_summary": "Gilbert, Arizona • Glendale, Arizona • Los Angeles, California + 17 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03491904" }, { "nct_id": "NCT05599984", "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ABBV-706", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 288, "start_date": "2022-12-05", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-11-01T01:42:30.964Z", "location_count": 22, "location_summary": "Gilbert, Arizona • Duarte, California • Irvine, California + 18 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05599984" }, { "nct_id": "NCT05259033", "title": "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "IcoSema", "type": "DRUG" }, { "name": "Semaglutide 1 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 683, "start_date": "2022-04-11", "completion_date": "2024-01-16", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-11-01T01:42:30.964Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City West", "state": "Arizona" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05259033" }, { "nct_id": "NCT04005352", "title": "Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Age-related Macular Degeneration" ], "interventions": [ { "name": "Brolucizumab 6 mg", "type": "BIOLOGICAL" }, { "name": "Aflibercept 2 mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 734, "start_date": "2019-09-25", "completion_date": "2022-09-09", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-11-01T01:42:30.964Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04005352" }, { "nct_id": "NCT00688038", "title": "Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Advanced Cancer", "Bone Metastases" ], "interventions": [ { "name": "Laser Ablation", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Thermal Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2008-05-13", "completion_date": "2017-09-12", "has_results": false, "last_update_posted_date": "2017-09-15", "last_synced_at": "2026-11-01T01:42:30.964Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00688038" }, { "nct_id": "NCT04100148", "title": "SyncAV Post-Market Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Congestive Heart Failure" ], "interventions": [ { "name": "SyncAV programmed ON", "type": "DEVICE" }, { "name": "Fixed AV delay", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1686, "start_date": "2019-10-03", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-11-01T01:42:30.964Z", "location_count": 30, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04100148" } ] }